Sawaya R, Cummins C J, Kornblith P L
Neurosurgery. 1984 Dec;15(6):795-800.
Four different intracranial neoplasms inhibited purified plasmin in an in vitro assay. The greatest inhibition (80%) was observed with extracts of a parasagittal meningioma that had invaded and completely occluded the sinus. Significant inhibition (greater than 40%) was also observed with extracts prepared from a glioma surgically removed from a patient who had suffered three thromboembolic episodes during the preceding several months. Lesser (less than 30%) inhibition was obtained with extracts from two other patients who had no evidence of thromboembolic complications. This report constitutes the first demonstration of plasmin inhibition activity in association with brain tumors. Further studies will be required to test the hypothesis that certain intracranial tumors may escape host antitumor fibrinolytic activity by producing plasmin inhibitors and that plasmin inhibitors may play a role in the thromboembolic complications frequently seen in patients with intracranial neoplasms.
在体外试验中，四种不同的颅内肿瘤抑制了纯化的纤溶酶。矢状窦旁脑膜瘤提取物对纤溶酶的抑制作用最强（80%），该脑膜瘤已侵犯并完全阻塞了静脉窦。从一名在过去几个月内发生过三次血栓栓塞事件的患者手术切除的神经胶质瘤提取物也观察到了显著的抑制作用（大于40%）。另外两名无血栓栓塞并发症证据的患者的提取物产生的抑制作用较小（小于30%）。本报告首次证明了与脑肿瘤相关的纤溶酶抑制活性。需要进一步研究来验证以下假说：某些颅内肿瘤可能通过产生纤溶酶抑制剂来逃避宿主的抗肿瘤纤维蛋白溶解活性，并且纤溶酶抑制剂可能在颅内肿瘤患者常见的血栓栓塞并发症中起作用。
